MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.ejmp.2026.105769

Медицинская библиотека · Physica medica : PM : an international journal devoted to the applications of physics to medicine and biology : official journal of the Italian Association of Biomedical Physics (AIFB) · 2026

Lesional dosimetry in 131I refractory metastatic differentiated thyroid cancer with BRAFp.V600E or RAS mutation treated with trametinib +/- dabrafenib followed by radioactive iodine.

Anizan Nadège, Pignard Alexandre, Borget Isabelle, Lamartina Livia, Schlumberger Martin, Broggio David, Leboulleux Sophie, Lamart Stéphanie

СтатьяКлиническое исследование II фазыПеревод пока не подготовлен

Аннотация

PURPOSE: In the MERAIODE phase II prospective trial (NCT03244956), patients with radioactive iodine refractory metastatic differentiated thyroid cancer (DTC) were treated with trametinib +/- dabrafenib before the administration of 5.5 GBq of 131I. A post-therapeutic lesional dosimetry study was conducted to assess the correlation between lesion absorbed doses and tumour response.

METHODS

Absorbed doses (AD) were calculated from four planar images acquired 1, 2, 3 and 4 days after 131I administration and normalized using a day-4 SPECT/CT. Lesional 131I activity was quantified on SPECT using a single calibration factor and a 50%SUVmax threshold segmentation. Lesion volumes were manually segmented on diagnostic CT scans acquired prior 131I and at 3, 6 and 9 months. Lesions were categorised using a 3D extrapolated RECIST 1.1 classification based on volumetric changes.

RESULTS

Median AD was higher in BRAFp.V600E mutated lesions (n = 19; 393.5 Gy [20.4-2906.3]) than in RAS mutated lesions (n = 6; 35.3 Gy [6.9-76.0]; p = 0.0005). At 6 months, 58% of BRAFp.V600E mutated lesions showed partial/complete response with a higher median AD (896 Gy) than stable/progressive lesions (183 Gy; p = 0.006). Eighty per cent of lesions receiving an AD above 393 Gy were classified as responders, whereas all lesions receiving an AD above 478 Gy were classified as responders.

CONCLUSION

The median AD was significantly higher in the BRAFp.V600E mutated DTC lesions than in the RAS mutated DTC lesions. BRAFp.V600E mutated DTC lesions with a partial and complete response received significantly higher doses than other lesions.

TRIAL REGISTRATION: NCT03244956, https://clinicaltrials.gov/study/NCT03244956.

Для цитирования: Anizan Nadège, Pignard Alexandre, Borget Isabelle, Lamartina Livia, Schlumberger Martin, Broggio David, Leboulleux Sophie, Lamart Stéphanie. Lesional dosimetry in 131I refractory metastatic differentiated thyroid cancer with BRAFp.V600E or RAS mutation treated with trametinib +/- dabrafenib followed by radioactive iodine.. Physica medica : PM : an international journal devoted to the applications of physics to medicine and biology : official journal of the Italian Association of Biomedical Physics (AIFB). 2026. DOI: 10.1016/j.ejmp.2026.105769.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.